Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Gerdts

Showing results (201-210 of 262) with videos related to

Pageof 27
Sort By:
Hypertension (Dallas, Tex. : 1979)|March 29, 2006
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension StudyPuneet Narayan, Vasilios Papademetriou, Kristian Wachtell, et al.
The American Journal of Cardiology|February 5, 2017
Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study)Marina De Marco, Eva Gerdts, Costantino Mancusi, et al.
American Heart Journal|September 25, 2004
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) studyKristian Wachtell, Vasilios Papademetriou, Gunnar Smith, et al.
European Journal of Preventive Cardiology|September 8, 2022
New perspectives for hypertension management: progress in methodological and technological developmentsGianfranco Parati, Alexandra Goncalves, David Soergel, et al.
Cardiology|January 24, 2022
Orientation of the Atrial Septum to the Inferior Vena Cava May Contribute to the Persistent Patency of the Foramen OvalePauli Pöyhönen, Jouni Kuusisto, Jani Pirinen, et al.
Journal of Hypertension|April 7, 2007
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE StudyVittorio Palmieri, Peter M Okin, Giovanni de Simone, et al.
The American Journal of Cardiology|September 22, 2010
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study)Kristian Wachtell, Vittorio Palmieri, Eva Gerdts, et al.
European Journal of Preventive Cardiology|October 14, 2022
Sex-specific time trends in incident atrial fibrillation and the contribution of risk factors: the Tromsø Study 1994-2016Ekaterina Sharashova, Eva Gerdts, Jocasta Ball, et al.
Journal of Hypertension|April 23, 2010
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction studyKristian Wachtell, Eva Gerdts, Vittorio Palmieri, et al.
The American Journal of Cardiology|October 13, 2004
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)Michael H Olsen, Kristian Wachtell, Jonathan N Bella, et al.
Pageof 27

Showing results (201-210 of 262) with videos related to

Sort By:
Pageof 27
Hypertension (Dallas, Tex. : 1979)|March 29, 2006
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension StudyPuneet Narayan, Vasilios Papademetriou, Kristian Wachtell, et al.
The American Journal of Cardiology|February 5, 2017
Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study)Marina De Marco, Eva Gerdts, Costantino Mancusi, et al.
American Heart Journal|September 25, 2004
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) studyKristian Wachtell, Vasilios Papademetriou, Gunnar Smith, et al.
European Journal of Preventive Cardiology|September 8, 2022
New perspectives for hypertension management: progress in methodological and technological developmentsGianfranco Parati, Alexandra Goncalves, David Soergel, et al.
Cardiology|January 24, 2022
Orientation of the Atrial Septum to the Inferior Vena Cava May Contribute to the Persistent Patency of the Foramen OvalePauli Pöyhönen, Jouni Kuusisto, Jani Pirinen, et al.
Journal of Hypertension|April 7, 2007
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE StudyVittorio Palmieri, Peter M Okin, Giovanni de Simone, et al.
The American Journal of Cardiology|September 22, 2010
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study)Kristian Wachtell, Vittorio Palmieri, Eva Gerdts, et al.
European Journal of Preventive Cardiology|October 14, 2022
Sex-specific time trends in incident atrial fibrillation and the contribution of risk factors: the Tromsø Study 1994-2016Ekaterina Sharashova, Eva Gerdts, Jocasta Ball, et al.
Journal of Hypertension|April 23, 2010
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction studyKristian Wachtell, Eva Gerdts, Vittorio Palmieri, et al.
The American Journal of Cardiology|October 13, 2004
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)Michael H Olsen, Kristian Wachtell, Jonathan N Bella, et al.
Pageof 27